- GMP
About
mAbxience is a vertically integrated biopharmaceutical company that develops and manufactures biologics, with a focus on biosimilars and innovator biologics. It provides end-to-end B2B development and CDMO services from R&D through commercial supply, with sites in Spain and Argentina.
Services
Biopharmaceutical development
Develops biologics with in-house R&D capabilities, including work specialized in biosimilars and innovator biologics.
CDMO services
Provides integrated development and manufacturing services tailored to client requirements, from research batches to commercial batches.
Cell line development and banking
Supports early-stage programs with cell line development and banking activities.
Cell line development
Analytical development
Develops analytical methods and capabilities to support development, validation, and manufacturing.
Process development
Develops robust and scalable processes for biopharmaceutical programs.
Formulation development
Develops formulations to support clinical and commercial supply.
Demo runs
Performs demo runs as part of early-stage development programs.
Clinical manufacturing
Produces clinical batches under GMP conditions.
CDMO: development & manufacturing
Tech transfer and manufacturing readiness
Supports technology transfer and readiness for manufacturing scale-up and transfer.
Process validation and analytical validation
Carries out validation work to support regulatory and manufacturing requirements.
cGMP manufacturing and commercial supply
Manufactures biologics for commercial supply and market needs.
CDMO: development & manufacturing
Quality and regulatory support
Provides quality and regulatory support across development and manufacturing activities.
- Turnaround
- IND ready in 12 months · Manufacturing-ready in 18 months
Capabilities
- Assays and studies
- Antibodies · Bioreactors · Analytical development · Process development · Analytical validation · Process validation
- Scale and capacity
- 3L-200L small scale GMP production · 200L clinical batches · 2L to 4,000L bioreactors · 6,000L bioreactors coming soon · 12,000L batches coming soon · Combined capacity of 50,000L · From 50,000L to 74,000L total capacity · 3 production sites · 5 production lines + 1 coming soon
Instruments and platforms
- Single-use bioreactors
Modalities and species
- Modalities
- Antibody · Bispecific · ADC · Cell therapy · Vaccine · Biosimilar
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Scope: production plants and small-scale GMP production
Company
- Type
- CRDMO
- Founded
- 2019
Locations
- Address
- biomanufacturing 2014 – 2015 Genhelix: mAbxience Spain R&D center First launch of
- Sites
- Spain, Spain · Argentina, Argentina · Madrid, Spain · Genhelix, Spain · Garín, Argentina · Munro, Argentina
- Serves
- worldwide, Europe, South America
Public records
Similar labs
Work here? Claim this listing